Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $740

Author: Benzinga Newsdesk | October 29, 2025 08:50am
Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $678 to $740.

Posted In: REGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist